Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G17DT in Colorectal Cancer
NCT02223078Phase 2Completed
- Sponsor
- Cancer Advances, Inc.
- Start
- Jul 2000
- Primary completion
- Aug 2001
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) comparing G17DT with Placebo (2 arms). Primary endpoint: Antibody Levels at 12 weeks. Started Jul 2000; status: completed.
02
Drugs
G17DT immunogen
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02223078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223078.